Visitor information – Everything you need to know about visiting our sites.
Alfred Health research outcomes are published in a wide range of peer reviewed journals.
Search or browse research publications by year, research area, publication type or keyword.
Publication Details
Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses
Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, Burton DR, Hogarth PM
(2014), J Immunol, 192(2), 792-803
Optimal approach for high-risk acute promyelocytic leukemia
Iland HJ, Seymour JF, Wei A
(2014), Curr Opin Hematol, 21(2), 102-13
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients
Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M
(2014), Clin Cancer Res, 20(3), 724-35
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M
(2014), Am J Hematol, 89(8), 795-802
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care
Iland HJ, Wei A, Seymour JF
(2014), Best Pract Res Clin Haematol, 27(1), 39-52
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A
(2014), Blood Cancer J, 4, e170
Causes and clinical significance of prolonged activated partial thromboplastin times in thalassaemia major
McFadyen J, Butler J, Malan E, Tran H
(2014), Ann Hematol, 93(5), 867-8
Prothrombin complex concentrate safely reverses warfarin-related bleeding
Tran H, Chunilal S
(2014), Evid Based Med, 19(2), 75
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)
Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J
(2014), Br J Haematol, 167(2), 243-51
An update of consensus guidelines for warfarin reversal
Tran HA, Chunilal SD, Tran H
(2014), Med J Aust, 200(2), 82
The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa
Htun KT, McFadyen J, Tran HA
(2014), Ann Hematol, 93(10), 1785-6
Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes
Tikellis C, Brown R, Head GA, Cooper ME, Thomas MC
(2014), Am J Physiol Renal Physiol, 306(7), F773-80
Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study
McQuilten ZK, Wood EM, Polizzotto MN, Campbell LJ, Wall M, Curtis DJ, Farrugia H, McNeil JJ, Sundararajan V
(2014), Cancer, 120(11), 1686-94
Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes
Crack PJ, Zhang M, Morganti-Kossmann MC, Morris AJ, Wojciak JM, Fleming JK, Karve I, Wright D, Sashindranath M, Goldshmit Y, Conquest A, Daglas M, Johnston LA, Medcalf RL, Sabbadini RA, Pébay A
(2014), J Neuroinflammation, 11, 37
Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL
McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, Tremblay CS, Rabbitts TH, Curtis DJ
(2013), Blood, 122(12), 2093-103
Cardiac imaging in FIP1L1-PDGFRA
Jaworski C, Looi JL, Martin J, Bergin P, Hare J, Kaye D, Wei A, Taylor AJ
(2013), J Am Coll Cardiol, 62(14), 1304
Stem cells behind the barrier
Cangkrama M, Ting SB, Darido C
(2013), Int J Mol Sci, 14(7), 13670-86
The regulation of mitochondrial metabolism by the Bcl-2fFamily of pro-survival proteins: new therapeutic opportunities for targeting cancer cells
Wei A, Brown M, Guthridge MA
(2013), J Hematol Thromb Dis, 1(4), 121
Efficacy, safety and survival with ruxolitinib in patients with smyelofibrosis: results of a median 2-year follow-up of COMFORT-I
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarj
(2013), Haematologica, 98(12), 1865-71
An investigation on platelet transport during thrombus formation at micro-scale stenosis
Tovar-Lopez FJ, Rosengarten G, Nasabi M, Sivan V, Khoshmanesh K, Jackson SP, Mitchell A, Nesbitt WS
(2013), PLoS One, 8(10), e74123